
Mechanisms & hormones
Glucagon-like peptide-1 (GLP-1)
Also found as: GLP-1 · GLP1 · glucagon-like peptide-1
The peptide signal whose receptor is targeted by GLP-1 receptor agonists. The STEP 1 extension describes semaglutide as a GLP-1 analogue.[1]
Source check: 2026-10-04 · Editorial method
How the research uses this term
The STEP 1 extension followed weight and cardiometabolic measures after the semaglutide treatment period ended. The active-treatment phase had compared semaglutide with placebo alongside lifestyle intervention.[1]
Reading the evidence
The tirzepatide biomarker paper distinguishes GLP-1 receptor activity from combined GIP and GLP-1 receptor activity. A shared receptor target does not make the two study interventions identical.[2]
Used in our guides
Continue reading where this term appears.
- TirzepatideRead the term in context
- SemaglutideRead the term in context
References
Definitions and explanations are paraphrased. The source locations below identify the supporting passages and methods.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionPrimary research · Human trial extension · 2022DOI: 10.1111/dom.14725
Source locations: Introduction; Materials and Methods.
Review status · PendingSource packet file
Weight_regain_and_cardiometabolic_effects_after_withdrawal_of_semaglutid_35441470_PMC9542252.pdf
- The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetesPrimary research · Human trial biomarker analysis · 2020DOI: 10.1111/dom.14174
Source locations: Introduction and Materials and Methods.
Review status · PendingSource packet file
The_dual_glucose_dependent_insulinotropic_peptide_and_glucagon_like_pept_33462955_PMC7756479.pdf